Salivary gland cancer clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For salivary gland cancer patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

Below is a list of salivary gland cancer clinical trials that are currently open and accepting patients at SCCA.
For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 6 of 6 trials

Start new search

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Investigator:

Cristina Rodriguez, MD

Study ID:

NCT01220583

View Trial

Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)

A Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Investigator:

Scott S. Tykodi, MD, PhD

Study ID:

NCT02904226

View Trial

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Investigator:

Christina S. Baik, MD, MPH

Study ID:

NCT02576431

View Trial

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

Investigator:

Gabriela Chiorean, MD

Study ID:

NCT02667873

View Trial

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Investigator:

Gabriela Chiorean, MD

Study ID:

NCT02568267

View Trial

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Investigator:

Heidi J. Gray, MD

Study ID:

NCT02834013

View Trial